History of research and development of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab

被引：0
|
作者：
Yoshida, Takao [1 ]
机构：
[1] Ono Pharmaceut Co Ltd, Reserch Ctr Oncol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SE2-4
引用
收藏
页码：693 / 693
页数：1
相关论文
共 50 条
  • [31] Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
    Starzer, Angelika M.
    Berghoff, Anna S.
    Hamacher, Rainer
    Tomasich, Erwin
    Feldmann, Katharina
    Hatziioannou, Teresa
    Traint, Stefan
    Lamm, Wolfgang
    Noebauer-Huhmann, Iris M.
    Furtner, Julia
    Muellauer, Leonhard
    Amann, Gabriele
    Bauer, Sebastian
    Schildhaus, Hans-Ulrich
    Preusser, Matthias
    Heller, Gerwin
    Brodowicz, Thomas
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
  • [32] Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
    Torrente-Lopez, Anabel
    Hermosilla, Jesus
    Salmeron-Garcia, Antonio
    Cabeza, Jose
    Navas, Natalia
    PHARMACEUTICS, 2022, 14 (04)
  • [33] Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.
    Ono, Ruriko
    Nakayama, Kentaro
    Itamochi, Hiroaki
    Nakamura, Kohei
    Sasamori, Hiroki
    Yamashita, Hitomi
    Ishibashi, Tomoka
    Ishikawa, Masako
    Ohnishi, Kaori
    Minamoto, Toshiko
    Iida, Kouji
    Ishikawa, Noriyoshi
    Otsuki, Yoshiro
    Kyo, Satoru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
    Kiasari, Bahman Abedi
    Abbasi, Arash
    Darestani, Nadia Ghasemi
    Adabi, Nasim
    Moradian, Arsalan
    Yazdani, Yalda
    Hosseini, Golsa Sadat
    Gholami, Nasrin
    Janati, Sheida
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [35] Durable remission with nivolumab, anti-PD-1 monoclonal antibody, in a patient with advanced thymic carcinoma
    Chae, Young Kwang
    Cho, Anderson
    Rhee, Kyunghoon
    Davis, Andrew
    Iams, Wade
    Bhave, Manali
    Cruz, Marcelo
    Park, Lee Chun
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
  • [37] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [38] A Case of Acute Myocarditis During Treatment With Anti-PD-1 Antibody Nivolumab in a Melanoma Patient
    Tadokoro, Tomonori
    Keshino, Eri
    Mohri, Masahiro
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (09) : S220 - S220
  • [39] Development of a diagnostic antibody for anti-BTN1A1 therapy, a novel immune checkpoint inhibitor mutually exclusive of PD-L1/PD-1
    Yoo, Stephen S.
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
    Daskivich, Timothy J.
    Belldegrun, Arie
    EUROPEAN UROLOGY, 2015, 67 (04) : 816 - 817
12345